CD4 and neoplasm: The study included 26 patients with colon cancer and 16 patients with rectal cancer; however, the percentage of circulating or tumor infiltrating CD4+Foxp3+LAP+ T cells in the CD4+Foxp3+ T cell population did not differ between the two groups of CRC patients (Fig 5B).